巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Finch Therapeutics Group

FNCH
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Finch Therapeutics Group - 延遲價格・最後更新於 14/01 12:14
最高位
9.180
最低位
8.740
開市價
--
前收市價
9.400
成交量(千)
2.63
成交額(百萬)
0.16
買入
--
賣出
--
每手股數
--
市值(百萬)
428.73
市盈率
--
息率
--
差價
--
52週高低
22.500 - 8.400
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Finch Therapeutics Group
證券代碼
FNCH.US
所屬板塊
Biotechnology
公司業務
Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.
發行量
47449147
公司總部
200 Inner Belt Road, Suite 400
公司網址
https://www.finchtherapeutics.com
公司電話
+1 617 229-6499
暫無內容

關於

Finch Therapeutics Group(FNCH.US)所屬的行業板塊為Biotechnology。
Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.
詳細公司背景可參考: https://www.finchtherapeutics.com